Improved Mass Spectrometry Assay For Plasma Hepcidin: Detection and Characterization of a Novel Hepcidin Isoform
Open Access
- 4 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10), e75518
- https://doi.org/10.1371/journal.pone.0075518
Abstract
Mass spectrometry (MS)-based assays for the quantification of the iron regulatory hormone hepcidin are pivotal to discriminate between the bioactive 25-amino acid form that can effectively block the sole iron transporter ferroportin and other naturally occurring smaller isoforms without a known role in iron metabolism. Here we describe the design, validation and use of a novel stable hepcidin-25+40 isotope as internal standard for quantification. Importantly, the relative large mass shift of 40 Da makes this isotope also suitable for easy-to-use medium resolution linear time-of-flight (TOF) platforms. As expected, implementation of hepcidin-25+40 as internal standard in our weak cation exchange (WCX) TOF MS method yielded very low inter/intra run coefficients of variation. Surprisingly, however, in samples from kidney disease patients, we detected a novel peak (m/z 2673.9) with low intensity that could be identified as hepcidin-24 and had previously remained unnoticed due to peak interference with the formerly used internal standard. Using a cell-based bioassay it was shown that synthetic hepcidin-24 was, like the -22 and -20 isoforms, a significantly less potent inducer of ferroportin degradation than hepcidin-25. During prolonged storage of plasma at room temperature, we observed that a decrease in plasma hepcidin-25 was paralleled by an increase in the levels of the hepcidin-24, -22 and -20 isoforms. This provides first evidence that all determinants for the conversion of hepcidin-25 to smaller inactive isoforms are present in the circulation, which may contribute to the functional suppression of hepcidin-25, that is significantly elevated in patients with renal impairment. The present update of our hepcidin TOF MS assay together with improved insights in the source and preparation of the internal standard, and sample stability will further improve our understanding of circulating hepcidin and pave the way towards further optimization and standardization of plasma hepcidin assays.Keywords
This publication has 37 references indexed in Scilit:
- Diurnal Rhythm rather than Dietary Iron Mediates Daily Hepcidin VariationsClinical Chemistry, 2013
- Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1Haematologica, 2013
- Serum levels of the hepcidin-20 isoform in a large general population: The Val Borbera studyJournal of Proteomics, 2012
- Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic SyndromesPLOS ONE, 2011
- Evaluation of Hepcidin Isoforms in Hemodialysis Patients by a Proteomic Approach Based on SELDI-TOF MSJournal of Biomedicine and Biotechnology, 2010
- An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodiesProceedings of the National Academy of Sciences of the United States of America, 2009
- SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standardProteome Science, 2008
- Advances in Quantitative Hepcidin Measurements by Time-of-Flight Mass SpectrometryPLOS ONE, 2008
- Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furinBlood Cells, Molecules, and Diseases, 2008
- How to measure and predict the molar absorption coefficient of a proteinProtein Science, 1995